Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [published erratum appears in J Exp Med 1992 Feb 1;175(2):621]

doi:10.1084/jem.174.6.1557

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Jiang, S. B.
	Articles by Neurath, A. R.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Jiang, S. B.
	Articles by Neurath, A. R.


Social Bookmarking

	What's this?

ARTICLES

Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41 [published erratum appears in J Exp Med 1992 Feb 1;175(2):621]

SB Jiang, K Lin and AR Neurath
Lindsley F. Kimball Research Institute, New York Blood Center, New York 10021.

Human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (gp120 and gp41) elicit virus-neutralizing antibodies (VNAB) and also antibodies enhancing HIV-1 infection (EAB). Several epitopes eliciting VNAB have been defined, the principal virus-neutralizing determinant being assigned to the V3 loop of gp120. To provide a background for a rational design of anti-HIV vaccines, it also appears important to define domains eliciting EAB. This was accomplished by screening antisera against synthetic peptides covering almost the entire sequence of gp120/gp41 for their enhancing effects on HIV-1 infection of MT-2 cells, a continuous T cell line. Many (16/30) of the antisera significantly enhanced HIV-1 in the presence of human complement. Antibodies to complement receptor type 2 (CR2) abrogated the antibody- mediated enhancement of HIV-1 infection. Antisera to V3 hypervariable loops of 21 distinct HIV-1 isolates were also tested for their enhancing effects on HIV-1IIIB infection. 11 of these sera contained VNAB and 10 enhanced HIV-1IIIB infection. All antisera with virus- enhancing activity contained antibodies crossreactive with the V3 loop of HIV-1IIIB, and the virus-enhancing activity increased with increasing serological crossreactivity. These results suggest that immunization with antigens encompassing V3 loops may elicit EAB rather than protective antibodies if epitopes on the immunogen and the predominant HIV-1 isolate infecting a population are insufficiently matched, i.e., crossreactive serologically but not at the level of virus neutralization.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

He, Y., Cheng, J., Li, J., Qi, Z., Lu, H., Dong, M., Jiang, S., Dai, Q. (2008). Identification of a Critical Motif for the Human Immunodeficiency Virus Type 1 (HIV-1) gp41 Core Structure: Implications for Designing Novel Anti-HIV Fusion Inhibitors. J. Virol. 82: 6349-6358 [Abstract] [Full Text]
He, Y., Xiao, Y., Song, H., Liang, Q., Ju, D., Chen, X., Lu, H., Jing, W., Jiang, S., Zhang, L. (2008). Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. J. Biol. Chem. 283: 11126-11134 [Abstract] [Full Text]
Vaillant, A., Juteau, J.-M., Lu, H., Liu, S., Lackman-Smith, C., Ptak, R., Jiang, S. (2006). Phosphorothioate Oligonucleotides Inhibit Human Immunodeficiency Virus Type 1 Fusion by Blocking gp41 Core Formation.. Antimicrob. Agents Chemother. 50: 1393-1401 [Abstract] [Full Text]
He, Y., Lu, H., Siddiqui, P., Zhou, Y., Jiang, S. (2005). Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies. J. Immunol. 174: 4908-4915 [Abstract] [Full Text]
Fichorova, R. N., Zhou, F., Ratnam, V., Atanassova, V., Jiang, S., Strick, N., Neurath, A. R. (2005). Anti-Human Immunodeficiency Virus Type 1 Microbicide Cellulose Acetate 1,2-Benzenedicarboxylate in a Human In Vitro Model of Vaginal Inflammation. Antimicrob. Agents Chemother. 49: 323-335 [Abstract] [Full Text]
Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., Debnath, A. K. (2004). N-Substituted Pyrrole Derivatives as Novel Human Immunodeficiency Virus Type 1 Entry Inhibitors That Interfere with the gp41 Six-Helix Bundle Formation and Block Virus Fusion. Antimicrob. Agents Chemother. 48: 4349-4359 [Abstract] [Full Text]
He, Y., Zhou, Y., Wu, H., Luo, B., Chen, J., Li, W., Jiang, S. (2004). Identification of Immunodominant Sites on the Spike Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Implication for Developing SARS Diagnostics and Vaccines. J. Immunol. 173: 4050-4057 [Abstract] [Full Text]
Liu, S., Boyer-Chatenet, L., Lu, H., Jiang, S. (2003). Rapid and Automated Fluorescence-Linked Immunosorbent Assay for High-Throughput Screening of Hiv-1 Fusion Inhibitors Targeting gp41. J Biomol Screen 8: 685-693 [Abstract]
Veljkovic, V., Metlas, R., Jevtovic, D., Stringer, W. W. (2001). The Role of Passive Immunization in HIV-Positive Patients : A Case Report. Chest 120: 662-666 [Abstract] [Full Text]
Ji, H., Shu, W., Burling, F. T., Jiang, S., Lu, M. (1999). Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. J. Virol. 73: 8578-8586 [Abstract] [Full Text]